Brain & cognitive performance
Cerebrolysin vs Omberacetam (Noopept)
Cerebrolysin has a broader RCT literature in neurologic disease but mixed indication-specific results; Noopept human evidence is smaller and more often.
At a glance
Cerebrolysin
Omberacetam (Noopept)
Human evidence
Multiple randomized trials and meta-analyses exist, but results differ by indication. Alzheimer trials show some short-term cognitive/global signals, whereas the 2023 Cochrane stroke review found no mortality benefit and a potential increase in non-fatal serious adverse events.
Human evidence consists mainly of older regional open/comparative studies in patients with vascular or traumatic cognitive impairment; no modern placebo-controlled healthy-adult cognitive-enhancement programme was identified.
Research focus
Alzheimer disease, acute ischaemic stroke, traumatic brain injury, cognitive recovery
Post-stroke cognitive impairment, mild cognitive impairment, neuroprotection; commonly discussed as a nootropic
Regulatory status
Regulatory availability varies by country; it is not an FDA-approved cognitive enhancer. Jurisdiction-specific product status must be checked separately.
FDA substance records identify omberacetam/Noopept but explicitly note that UNII listing does not imply regulatory review or approval. Regulatory status varies internationally.
Route / formulation
Evidence applies to a specific biologic mixture formulation, commonly administered intravenously in trials; generic 'peptide blends' are not equivalent.
Most clinical literature concerns oral use in neurologic patients; it should not be extrapolated to other formulations or healthy-user 'nootropic' protocols.
No direct head-to-head trial identified Cerebrolysin has a broader RCT literature in neurologic disease but mixed indication-specific results; Noopept human evidence is smaller and more often open/comparative.